P.F. Wadsworth

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes et al. · PubMed · 2002 · 802 citations

Oral Administration, Pharmacotherapy, Tumor Biology +18

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 706 citations · Full text

Revised guides for organ sampling and trimming in rats and mice – Part 2

Birgit Kittel, Christine Ruehl-Fehlert, Gerd Morawietz et al. · Experimental and Toxicologic Pathology · 2004 · 329 citations

Organ Physiology, Physiology, Biostatistics +2

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Stephen R. Wedge, DJ Ogilvie, Michael Dukes et al. · PubMed · 2000 · 194 citations

Chemoprevention Strategy, Immunology, Pathology +18

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.

Seiichi Yano, Kaoru Kondo, Motonori Yamaguchi et al. · PubMed · 2004 · 182 citations

Pathology, Cell Proliferation, Dermatology +18